Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
20 August 2020 | Story Andre Damons | Photo Barend Nagel
Prof Motlalepula Matsabisa, Associate Professor in the Department of Pharmacology at the University of the Free State (UFS), has been appointed as the chairperson of the World Health Organisation’s (WHO) Regional Expert Advisory Committee on Traditional Medicines for COVID-19.

Prof Motlalepula Matsabisa, Associate Professor in the Department of Pharmacology at the University of the Free State (UFS), will lead Africa’s fight against the COVID-19 pandemic with his appointment as chairperson of the World Health Organisation’s (WHO) Regional Expert Advisory Committee on Traditional Medicines for COVID-19.

Prof Matsabisa has been chosen over 25 other experts from 27 African countries to head this expert committee tasked with setting up research and clinical trials for COVID-19 and beyond. The committee is also supported by the African Union (AU), the Centers for Disease Control and Prevention (CDC – Africa), and the European and Developing Countries Clinical Trials Partnership (EDCTP).

This committee was established by the WHO and the Africa CDC on 22 July with the aim of providing independent scientific advice and support to countries on the safety, efficacy, and quality of traditional medicine therapies. It is also an effort to enhance research and development of traditional medicines for COVID-19 in Africa.

Looking forward

“This is a huge continental and global responsibility being laid on my shoulders as a chairperson.  I have to keep the committee together and ensure that it delivers on its set mandate and terms of reference.  I need to ensure that the committee helps the continent and region to get the scientific and legislative aspects on traditional medicine development on track.”  

“I have taken this position and responsibility, knowing quite well what it entails. I want to do this for the continent and for the sake of good science of all traditional healers and consumers of traditional medicines on the continent and beyond,” says Prof Matsabisa.

According to Prof Matsabisa, he is looking forward to working with a team of dedicated experts from 27 countries in the African region, and being of help to countries that need assistance with clinical trials, including preclinical work to move to clinical research.

Prof Matsabisa says he is also looking forward to countries asking South Africa to be part of their multi-centre studies in clinical trials for traditional medicines, and to help set up clinical trial teams that include Western-trained clinicians to get into traditional medicine studies. 

The work of the committee

According to Prof Matsabisa, his new position took effect the same day as his appointment and will run as long as COVID-19 is part of our daily lives and even beyond. It entails supporting member states to implement the WHO master plan for clinical trial protocols in order to generate credible data for COVID-19 results, based on traditional medicines. The committee will also coordinate support to member states in the African region to collaborate on clinical trials of traditional medicine-based therapies – elevating standards by pooling expertise in multicentre studies, as well as complying with GCP and good participatory practice guidelines for trials of emerging and re-emerging pathogens.
“The committee will also advise on strengthening the capacity of national medicine regulatory authorities to accelerate the issuance of marketing authorisations for traditional medicine products that have been well researched for safety, efficacy, and quality, as well as to expedite the approval of clinical trials on traditional medicines. This will help to meet the national registration criteria and the WHO norms and standards of quality, safety, and efficacy for the management of COVID-19 and others.”

“It will also provide independent scientific advice to the WHO and other partners regarding policies, strategies, and plans for integrating traditional medicines into COVID-19 responses and health systems,” explains Prof Matsabisa. 

Aiming for the top spot 

Prof Matsabisa has been described as having the third highest research output – something he is not satisfied with. 
“I was disappointed that only one point separated me from the second place. I will push for first place as this is my ultimate aim. My motivation for this is simple – I like what I am doing, I do not take it as a job but do it because I love research.”  

“I always like to tell students that we should be proud to one day see products in the shops that we can relate to and to which we have contributed or that we have made.   This is what drives me and my staff.  I have a beautiful team of students, staff, and postdoctoral fellows who share my vision of research.  We all have a shared vision and strive to be relevant at all times in science research, development, and teaching.”

• Prof Matsabisa was recently part of a national conference with the theme: Harnessing science, technology, and innovation in response to COVID-19: A national and international effort. The conference was hosted by Dr Blade Nzimande, Minister of Higher Education, Science and Innovation, with Pres Cyril Ramaphosa, Dr Zweli Mkhize, Minister of Health, Ebrahim Patel, Minister of Trade, Industry and Competition, Prof Sarah Anyang Agbor, African Union Commissioner for Human Resources, Science and Technology, and Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organisation, in attendance. 

News Archive

Conference: Expanded ARV treatment
2005-03-02

VENUE: University of the Free State, Bloemfontein, South Africa
DATE: 30 March 2005 - 1 April 2005

  • ARV Programme as on 24Feb Download Word document
     
  • Programme Special events Download Word document


    Official web site www.fshealth.gov.za/subsites/arvc

     


    Rationale for the Conference
    At the time of the planned Conference, much ground would have been covered, both in the Free State and in South Africa, in respect of the expanded public sector ARV treatment programme in respect of research, experiences in practice, training of staff, treatment of patients, lessons learned, successes and failures, etc. The time would then be quite opportune to share these in a systematic manner with other provinces and countries, as well as with the large variety of stakeholders and role players in the ARV and related domains, be they academics and researchers, policy makers and service/facility managers, the variety of caregivers, and the community organisations and affected patients.

The Conference and current research
The proposed Conference is, firstly, directly linked to the current research on the public sector roll-out of ARV treatment in the Free State conducted by several research institutions (e.g. CIET, CHSR&D, UCT Lung Institute). Secondly, the Conference could and would serve as a forum for other research groups in the country and further a field to report and share knowledge and experiences on ARV treatment and related initiatives. Lastly, the Conference will stage a golden opportunity for researchers and scientists, on the one hand, and policy makers, managers, and caregivers (as knowledge users), on the other hand, to engage in cross-disciplinary discourse on this mutual and topical theme.

Theme of Conference
Expanded ARV treatment in the Free State: sharing experiences

Focus
The focus is primarily on public sector ARV treatment in the Free State, but also initiatives/activities/perspectives of relevance to the Free State elsewhere in the country at large and further a field, as well as relevant ARV initiatives in the public, private, NGO and FBO sectors. Bear in mind, however, that ARV treatment is but part of a much more comprehensive approach to HIV and AIDS. The Conference will, therefore, not narrowly focus on the ARV treatment programme only. The broader context, other relevant dimensions, and a comprehensive approach to the challenges of HIV, AIDS and TB are of equal importance.

The purpose of the Conference
Enhance meaningful exchange, mutual understanding and collaboration among researchers, scientists, policy makers, managers and practitioners in the field of ARV treatment and related fields.

Share experiences in the various spheres of ARV treatment and related spheres (policy, management, practice, research, training, public-private-civil society sectors).

Record, reflect and report on the establishment of the ARV treatment programme in the Free State, and in within the context of the comprehensive HIV/AIDS programme.

Disseminate important research results on ARV treatment and related themes to health policy makers, managers, practitioners, communities and to the research community.

Stimulate discourse among various disciplines and various stakeholders/role players involved in ARV treatment and related programmes.

Sensitise and acquaint researchers to the requirements of policy makers, managers and practitioners in respect of ARV treatment and related fields.

Facilitate the implementation of research results in ARV treatment policy, programmes and practice.

Dissemination of Conference-related information
Information generated during the Conference could feed into policy, management and practice of ARV treatment, the training accompanying such programme, and the existing body of knowledge. After the Conference the information will be disseminated via the Internet and by scientific and popular publications.

Date and duration
Set for 30 & 31 March & 1 April 2005; to commence at 09:00 on the first day (30 March) and to end at 16:30 (1 April) the third day.

Format and scope of Conference
Alternating plenary, parallel sessions and debates focused on topical issues and interest groups. The Conference will strive to be maximally interactive and participative.

Themes and topics to cover:

  • Policy, management and health services/practice (various levels and contexts – clinical treatment, information, IT systems, pharmacy, laboratories, nutrition)
     
  • Research covering all relevant disciplines and diverse dimensions of ARV treatment and related themes
  • Training and evaluation of training
  • Patients, communities and civil society organisations
  • Public, private, NGO, FBO initiatives and partnerships

Emphasis will be on the Free State, however, with of significant involvement from other provinces, SADC countries, and countries further a field. The thrust will be to export lessons and experiences from the Free State, but also to import lessons and experiences from other provinces, countries and sectors.

Presenters
Key presenters from the Free State, other provinces, South Africa, from the private, FBO and NGO sectors, and from several other countries

Delegates
About half of the delegates will be Free State stakeholders and role players (all levels and all contexts). The other half will be role players and stakeholders in the ARV and related fields from other provinces, the national level, and other countries, as well as from the private, public and non-governmental sectors.

Focused workshops
Provision will be made for half-a-day or one-day workshop initiatives on the third day (1 April 2005).

Enquiries
For more information please contact:

Prof Dingie van Rensburg
Centre for Health Systems Research & Development
University of the Free State
PO Box 339
Bloenfontein
SOUTH AFRICA
9300

Contact:
Carin van Vuuren
Conference Organiser
Centre for Health Systems Research & Development
University of the Free State
P.O.Box 339
Bloemfontein
South Africa
9300
Tel +27 (0) 51 401 2181
Fax +27 (0) 51 4480370
Cell 0832932890
e-mail: arvconference.hum@mail.uovs.ac.za

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept